Physician profile
Jeffrey Lyons
NPI 1851386908
$1,822.36
in general payments reported to CMS, 2019-2025
22 companies · $975 in 2025
The $975 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $113 · 2020: $38.38 · 2023: $255 · 2024: $440 · 2025: $975.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,671.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,670.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $277.37 | 2023-2025 | |
| Exact Sciences Corporation | $262.70 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbott Laboratories | $203.43 | 2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $150.67 | 2024-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $137.31 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Otsuka America Pharmaceutical, INC. | $115.82 | 2023 | Rexulti |
| Sunovion Pharmaceuticals INC. | $113.37 | 2019 | |
| Amgen INC. | $101.37 | 2024-2025 | Repatha, Otezla, Prolia |
| Novartis Pharmaceuticals Corporation | $76.82 | 2025 | |
| Globus Medical, INC. | $49.16 | 2025 | Senza |
| Abbvie INC. | $45.66 | 2023-2024 | |
| Eisai INC. | $38.72 | 2025 | |
| Janssen Pharmaceuticals, INC | $38.38 | 2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $37.88 | 2024 | Lifevest |
| Phathom Pharmaceuticals, INC. | $29.05 | 2024-2025 | Voquezna |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $26.90 | 2024 | Ingrezza |
| Glaxosmithkline, LLC. | $24.32 | 2025 | Shingrix |
| Dexcom, INC. | $22.74 | 2024 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $18.86 | 2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.62 | 2025 | Jardiance |
| Phadia US INC. | $16.88 | 2024 | Immunocap |
| Alnylam Pharmaceuticals INC. | $16.33 | 2025 | Onpattro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Lyons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.